Los Angeles Talc Ovarian Cancer Verdict: What Johnson & Johnson’s Defense Win Means for Your Case
If you are reading this because you used talc-based baby powder for years and later heard the words “ovarian cancer” from a doctor — or because someone you love is gone and you are only now connecting the powder on the bathroom shelf to the disease that took them — you need to know what just happened in a Los Angeles courtroom and what it means for you. A jury in Los Angeles County returned a defense verdict for Johnson & Johnson in a wrongful death action brought by the families of three women who allegedly developed and died from ovarian cancer after prolonged use of J&J’s talc-based baby powder. The jury concluded that J&J was not negligent in the marketing and sale of its cosmetic talc products. That is a real outcome in a real trial, and we will not minimize it. But it is one verdict in one courtroom on one set of facts — and the honest truth about this litigation is that verdicts across the country have gone in both directions, some for the families and some for the company. What happened in Los Angeles does not close your door. It tells you what the fight looks like and what it takes to win it. We are Attorney911 — The Manginello Law Firm, PLLC, and this page is our senior trial team’s analysis of what this verdict means, what the science actually says, what California law allows, and what you should do if you or a family member used these products and developed this disease.
What Happened in This Los Angeles Trial
The case was tried in Los Angeles County, California — a venue with a long history of plaintiff-favorable product liability verdicts against corporate manufacturers, which makes this defense verdict notable. The families of three women — Mary Owens, Bonnie Tienken, and Geneva Williams — alleged that their loved ones developed and died from ovarian cancer after years of perineal use of J&J’s talc-based baby powder. The plaintiffs pursued negligence, strict product liability (failure to warn and design defect), and wrongful death theories against Johnson & Johnson. After reviewing the evidence, the jury rejected those claims, finding that J&J was not negligent in the marketing and sale of its cosmetic talc products.
The critical fact is what the jury was asked to decide and what it decided. The central question was causation — whether talc exposure from perineal use of baby powder can cause ovarian cancer, and whether it caused these specific women’s cancers. J&J’s defense centered on the argument that the scientific evidence does not establish a causal link between cosmetic talc use and ovarian cancer. The jury agreed with that argument, or at least was not persuaded that the plaintiffs had met their burden of proof on causation.
This matters because it reveals the single hardest fight in every talc-ovarian cancer case: general causation. Not whether J&J knew something. Not whether the warning label was adequate. Whether the product can cause the disease at all. That is where these cases are won or lost, and that is where the defense invests its heaviest resources — in elite epidemiologists and gynecologic oncologists who testify that the association between talc and ovarian cancer is weak, inconsistent, and not proven.
Does This Verdict Mean I Cannot Win My Talc Case?
No. This verdict is one jury’s assessment of one set of plaintiffs’ evidence in one trial. It does not establish that talc is safe. It does not create binding precedent for other cases. It does not prevent you from filing a claim. And it does not reflect the outcome of every talc trial that has been held — because the verdict record across this litigation is genuinely mixed.
Johnson & Johnson has won several recent trials, including a case in Oklahoma. But other juries in other courthouses have returned significant plaintiff verdicts. The largest and most widely reported was a Missouri case involving 22 women — Ingham v. Johnson & Johnson — where a jury awarded $4.69 billion in July 2018. On appeal, the Missouri Court of Appeals reduced that figure to approximately $2.12 billion. The United States Supreme Court declined to review the case in June 2021, which means the reduced award stands as a final, affirmed recovery. That is a real number, paid by the same company, for the same type of claim — and it tells you that the science is not so weak that no jury will buy it. It tells you that the outcome depends on the quality of the evidence, the strength of the experts, the venue, and the specific facts of who used what, for how long, and how their disease developed.
What the Los Angeles defense verdict does signal is that J&J will not roll over. The company has decided to fight these cases in the tort system after three failed attempts to resolve them through bankruptcy. And when they fight, they fight hard — with top-tier defense lawyers, well-funded expert witnesses, and a narrative built around regulatory compliance and scientific uncertainty. If you are considering a claim, you need to know exactly what you are walking into. That is why this page exists.
The Science Battleground: Does Talc Cause Ovarian Cancer?
This is the heart of every talc-ovarian cancer case, and it is the fight that decided the Los Angeles trial. Here is what the science actually looks like, in plain language, from the perspective of a trial team that has to prove or disprove it.
The exposure pathway. The theory is that talc particles applied to the perineal area — the region between the vagina and the anus — can travel through the vagina, through the cervix and uterus, and up through the fallopian tubes to the ovaries. Once there, the theory holds, these particles cause chronic inflammation that over time can contribute to malignant transformation of ovarian cells. Talc particles have been found in ovarian tissue in some studies, which supports the biological plausibility of this pathway. But the evidence is not uniform, and the defense attacks both the pathway (can the particles actually reach the ovaries?) and the mechanism (does inflammation from talc actually cause cancer?).
The epidemiology. Multiple case-control studies over decades have examined whether women who used talc in the perineal area had higher rates of ovarian cancer than women who did not. Some of these studies found a modestly elevated risk — typically in the range of a 20 to 40 percent increase, which sounds significant but is considered a “weak association” in epidemiological terms. Other studies, including some larger cohort studies, found no statistically significant association. The defense seizes on this inconsistency and argues that a weak, inconsistent epidemiological record cannot support a causal conclusion. The plaintiffs’ experts argue that the consistency of the modest elevated risk across many studies, combined with the biological plausibility of the pathway, supports causation. This is a genuine scientific dispute — not a frivolous claim, but not a settled one either.
The regulatory classification. The International Agency for Research on Cancer — the World Health Organization’s cancer research arm — has classified perineal use of talc-based body powder as possibly carcinogenic to humans. That classification does not mean talc definitely causes ovarian cancer. It means the world’s leading cancer research agency concluded there is enough evidence to warrant concern. The defense will point out that “possibly carcinogenic” is a cautious classification, not a definitive one — and that the FDA has not banned talc in cosmetics or required ovarian cancer warnings.
Cosmetic products containing talc are regulated by the U.S. Food and Drug Administration under the Federal Food, Drug, and Cosmetic Act, which does not require pre-market approval for cosmetic ingredients.
That regulatory fact is both a shield for J&J and a gap in the system. The FDA’s authority over cosmetics is famously thin — the agency cannot even order a mandatory recall of a cosmetic product. The absence of an FDA ban or warning requirement does not mean the product is safe; it means the regulatory system for cosmetics in this country does not require the kind of pre-market safety testing and post-market surveillance that applies to drugs and medical devices. J&J’s voluntary withdrawal of talc-based baby powder from the U.S. market in 2020 — replacing it with a cornstarch formulation — occurred amid mounting litigation and regulatory scrutiny, not because of any formal FDA ban or recall order. The company has said the withdrawal was a commercial decision driven by changing consumer preferences. A jury can decide for itself what to make of a company that pulls a product off the shelf while simultaneously arguing in court that it is perfectly safe.
Why the Los Angeles jury might have rejected causation. Without seeing the trial transcript, we can identify the most likely reasons a jury would reject the causal link. First, ovarian cancer has many known risk factors — BRCA gene mutations, family history, age, nulliparity (never having given birth), endometriosis, hormone replacement therapy — and the defense will emphasize these alternative explanations. Second, proving specific causation (that talc caused THIS woman’s cancer) is even harder than proving general causation (that talc can cause cancer at all). Third, the exposure evidence has to be strong — documented, long-term, perineal use — and decades after the fact, that evidence can be thin. Fourth, the defense’s experts may have been more persuasive on the scientific uncertainty than the plaintiffs’ experts were on the causal link. Any one of these, or a combination, can produce a defense verdict even when the science is genuinely contested.
California Product Liability Law: The Framework That Governs Your Case
California is the state that invented modern strict product liability. The doctrine — established by the California Supreme Court in the 1960s — holds that a manufacturer is liable for injuries caused by defective products regardless of whether the manufacturer was negligent. This is a powerful advantage for plaintiffs in California compared to states that require proof of negligence. In a strict liability case, you do not have to prove the company was careless. You have to prove the product was defective and that the defect caused the injury.
Three theories of defect. In California, a product can be defective in three ways. A manufacturing defect exists when a product departs from its intended design — not applicable here, because the talc powder was presumably manufactured as intended. A design defect exists when the product is inherently dangerous in design — here, plaintiffs argued that talc-based powder was defectively designed because a safer alternative (cornstarch) was available and J&J ultimately substituted it in 2020. A failure to warn defect exists when the product lacks adequate warnings about known or reasonably foreseeable dangers — here, the central argument was that J&J failed to warn consumers about the alleged ovarian cancer risk associated with perineal talc use.
The consumer expectations test and the risk-benefit test. California applies both tests for design defect. Under the consumer expectations test, a product is defective if it fails to perform as safely as an ordinary consumer would expect when used in an intended or reasonably foreseeable way. Under the risk-benefit test, a product is defective if the dangers of the design outweigh its benefits and a safer alternative design was feasible. In talc cases, plaintiffs typically argue both: that consumers did not expect baby powder to cause cancer (consumer expectations) and that the risk of cancer outweighed the benefit of talc over cornstarch (risk-benefit).
No caps on non-economic damages in product liability cases. This is one of California’s strongest advantages for plaintiffs. California’s MICRA (Medical Injury Compensation Reform Act) caps non-economic damages — but only in medical malpractice cases. Product liability actions are not subject to MICRA. This means that had the plaintiffs in this Los Angeles trial prevailed, there would have been no statutory ceiling on the pain and suffering, loss of consortium, and loss of society and companionship damages a jury could award. Three wrongful death claims against a deep-pocket manufacturer, with no non-economic damage cap and potential punitive damages exposure, could have produced a substantial verdict.
Pure comparative fault. California follows a pure comparative fault rule, meaning a plaintiff’s recovery is reduced by their percentage of fault but is never barred entirely — even if the plaintiff is 99 percent at fault, they can still recover 1 percent of their damages. In talc cases, the defense may argue that the plaintiff assumed the risk by continuing to use the product after public warnings appeared, or that the plaintiff’s own genetic or lifestyle factors contributed to the cancer. In this trial, fault allocation was not the decisive factor — the jury rejected causation entirely — but in a case that survives the causation fight, comparative fault becomes a battleground where every percentage point is money.
Expert testimony admissibility. California’s evidentiary standard for expert testimony follows a general acceptance test for novel scientific evidence, which can create admissibility hurdles for emerging causation theories in toxic tort litigation. California courts also exercise a gatekeeping function over expert testimony to ensure it rests on a sound methodological foundation. This matters in talc cases because the causation science is contested — if the defense can convince a judge that a plaintiff’s epidemiology expert is relying on methodology that is not generally accepted in the scientific community, that expert’s testimony may be excluded, and without expert testimony on causation, the case cannot reach a jury. This is one of the defense’s most powerful tools, and it is a threshold fight that can decide the case before opening statements.
Punitive damages. California Civil Code allows punitive damages for despicable conduct carried on with a willful and conscious disregard for the safety of others. In talc cases, plaintiffs seek punitive damages by pointing to internal corporate documents that allegedly show J&J knew about cancer risk concerns years before the 2020 market withdrawal and failed to warn consumers. Whether those documents meet the punitive damages standard is a case-specific question, but the potential is real — and in California, punitive damages in product liability cases are not capped.
The Clock: How Long You Have to File in California
California’s statute of limitations for wrongful death actions requires that a claim be filed within two years of the date of death. This is governed by California’s Code of Civil Procedure, which provides a two-year limitations period for actions arising from the death of an individual caused by the wrongful act or neglect of another. The clock starts on the date of death — not the date of diagnosis, not the date the connection to talc was discovered, and not the date J&J withdrew the product from the market.
For survival claims — which capture the decedent’s own pre-death damages, including pain and suffering between injury and death — the limitations period is also generally two years, but the accrual date may differ. If the underlying claim is one that the decedent could have brought during their lifetime, the survival claim’s clock may start when the decedent discovered or should have discovered the injury and its cause.
The discovery rule is critical in talc-ovarian cancer cases. Ovarian cancer can develop years or decades after exposure begins, and the alleged causal link between cosmetic talc use and ovarian cancer has only become widely publicized in recent years. A plaintiff who was diagnosed with ovarian cancer years ago but only recently learned of the possible connection to talc may argue that the statute of limitations should run from the date of discovery, not the date of diagnosis. This is a litigated issue, and the outcome depends on the specific facts and the jurisdiction — but the principle is real, and it is why you should not assume you are too late without consulting a lawyer who can evaluate your specific timeline.
If your loved one has already passed away, the two-year clock from the date of death may be running right now. If you were diagnosed with ovarian cancer and are still living, the clock may run from the date you discovered or should have discovered the connection between your disease and talc exposure. Either way, the deadline is unforgiving — miss it and the case is over, no matter how strong the evidence is.
If you or a family member needs help understanding the wrongful death claim process, the deadline is the first thing to evaluate.
Johnson & Johnson: The Company Behind the Powder
Johnson & Johnson is not just a defendant — it is one of the largest and most financially powerful corporations in the world, with a market capitalization in the hundreds of billions of dollars. Understanding the corporate structure matters because the entity that sold the product, the entity that holds the liability, and the entity that holds the assets may not be the same.
The corporate structure. Johnson & Johnson is the parent corporation, headquartered in New Brunswick, New Jersey. The consumer products division that manufactured and sold talc-based baby powder operated through Johnson & Johnson Consumer Inc. (JJCI), a subsidiary. In 2023, J&J spun off its consumer health business into a separate publicly traded company called Kenvue Inc. — which now owns brands like Band-Aid, Tylenol, and Listerine. J&J retained indemnity obligations related to talc liability, meaning the parent company — not Kenvue — is responsible for defending and resolving talc claims.
The bankruptcy shell game. The most significant structural maneuver in this litigation was J&J’s use of a legal strategy known as the “Texas two-step” — a divisional merger under Texas law that split a subsidiary into two entities: one that held the valuable business assets and one (LTL Management LLC, later renamed Red River Talc LLC) that held the talc liability. The liability entity then filed for Chapter 11 bankruptcy, attempting to use the bankruptcy process to force a global settlement of all talc claims through a court-supervised trust — similar to how asbestos claims have been resolved. This would have capped J&J’s total talc exposure and channeled all claims into a trust with a fixed payment matrix.
Three times J&J attempted this strategy. Three times it failed. The first two bankruptcy filings were dismissed by courts that found the entity did not face financial distress sufficient to justify bankruptcy — J&J, the ultimate funding source, had the resources to pay claims in the tort system. The third attempt — filed by Red River Talc LLC in the Southern District of Texas — was denied and dismissed on March 31, 2025, when the bankruptcy court found vote-solicitation irregularities and impermissible nonconsensual third-party releases. With all three bankruptcy attempts behind it, J&J has pivoted back to defending cases in the tort system — which is exactly what happened in this Los Angeles trial.
The MDL. More than 68,000 talc-ovarian cancer and mesothelioma claims are consolidated in a federal multidistrict litigation — MDL No. 2738 — before Judge Michael A. Shipp in the District of New Jersey. The MDL centralizes pretrial proceedings (discovery, expert challenges, bellwether trials) but does not merge the cases into a class action. Each plaintiff retains an individual claim. The MDL’s bellwether trials — test cases designed to help both sides assess settlement value — have produced mixed results, which is part of why the overall docket remains unresolved after years of litigation.
The product withdrawal. J&J discontinued sales of talc-based baby powder in the United States in 2020, replacing it with a cornstarch-based formulation. The company has stated this was a commercial decision driven by changing consumer preferences and misinformation. Plaintiffs argue the withdrawal was a response to mounting litigation and negative publicity — and that a company pulling a product it insists is safe is an admission by conduct that a jury can consider.
Coverage reality. J&J is what we call a balance-sheet defendant. It is largely self-insured for mass tort liability. There is no insurance policy with a published limit that caps recovery. The company’s own assets stand behind every judgment — which means there is money to recover if you win, but there is also no insurance company pressuring J&J to settle to avoid trial costs. This is a company that can afford to fight every case, and it has chosen to do so.
The 67,000-Plaintiff Talc Litigation: Mixed Verdicts and What They Mean
The Los Angeles defense verdict is part of a sprawling mass tort involving more than 67,000 plaintiffs nationwide who claim J&J’s talc-based products caused ovarian cancer or mesothelioma. The verdict record is genuinely mixed, and understanding that record is essential to evaluating your own case.
Plaintiff verdicts. The most significant plaintiff verdict remains Ingham v. Johnson & Johnson, the Missouri case involving 22 women who claimed talc use caused their ovarian cancer. The jury awarded $4.69 billion in July 2018. On appeal, the Missouri Court of Appeals reduced the award to approximately $2.12 billion, and the United States Supreme Court declined to review the case in June 2021. That reduced award stands as a final, affirmed recovery — real money, paid by J&J, for the same type of claim at issue in the Los Angeles trial. Other plaintiff verdicts have been reported in various jurisdictions, with awards ranging from millions to tens of millions of dollars.
Defense verdicts. J&J has also won trials, including the Oklahoma case referenced in the reporting on this Los Angeles verdict and now this Los Angeles case itself. The defense’s strategy is consistent across these wins: attack the science, emphasize regulatory compliance, point to alternative causes of ovarian cancer, and argue that the plaintiff has not proven sufficient exposure or specific causation.
What mixed verdicts tell you. Mixed verdicts in mass tort litigation tell you several things. First, the outcome of any individual case depends heavily on its specific facts — the strength of the exposure evidence, the quality of the medical records, the persuasiveness of the experts, and the venue. Second, the science is genuinely contested, and reasonable juries can reach different conclusions when presented with the same general evidence. Third, settlement dynamics become complicated — a defense verdict like this one may depress per-claim settlement values across the broader docket, while a plaintiff verdict raises them. Fourth, if you have a strong individual fact pattern — documented long-term perineal use, a clear ovarian cancer diagnosis, pathology that supports the causal theory, and minimal alternative risk factors — you may be better served by an individual trial track than by accepting a global settlement average.
Evidence Preservation: What Exists and How Fast It Disappears
In a talc-ovarian cancer case, the evidence is different from a crash case — there is no dashcam footage or black box to download. But the evidence is still perishable, and some of it is on a clock that has already been running for years.
J&J internal corporate documents. The most powerful evidence in talc cases is often the company’s own internal records — safety testing memos, communications about cancer risk concerns, marketing documents showing how the product was promoted for perineal use, and documents showing when J&J became aware of studies linking talc to ovarian cancer. These documents are subject to litigation holds in active cases, but document retention policies vary across corporate entities and subsidiaries. Documents that are not under a hold may be subject to destruction under corporate retention schedules. If you are considering a claim, the preservation demand that freezes these documents should go out early — but that demand only works if a lawyer sends it while the documents still exist.
Product samples and batch records. The talc-based baby powder was discontinued in the U.S. market in 2020. Remaining product samples — the actual bottles and containers a plaintiff used — can potentially be tested for asbestos contamination and crystalline silica content, which links the specific product formulation to the exposure evidence. But samples degrade over time, containers are discarded, and once the product is gone, it is gone. If you still have bottles of talc-based baby powder that you or a loved one used, keep them. Do not discard them. They are physical evidence.
Decedents’ medical records, pathology reports, and preserved tissue blocks. These are the documents that establish the diagnosis, the cancer subtype, the stage at diagnosis, and — in some cases — evidence of talc particles in ovarian tissue. Medical records are subject to facility retention schedules, and pathology blocks (preserved tissue samples) may be discarded after statutory retention periods expire. If your loved one has passed away, their medical records may still exist, but the clock on how long the facility must keep them is running. Request the complete medical record — including pathology reports, surgical pathology slides, and tissue blocks — before routine destruction schedules thin or eliminate them.
Epidemiological studies and FDA/NIH research. The scientific literature on the talc-ovarian cancer association is durable — published studies do not disappear. But the interpretation of that literature shifts as new meta-analyses are published and as the scientific community’s consensus evolves. The evidence landscape today may look different from the landscape in two years, and a case built on the current science may be stronger or weaker depending on what new studies emerge.
Marketing and advertising archives. J&J’s marketing materials for talc-based products — spanning decades of print, television, and digital advertising — demonstrate how the product was promoted and whether it was marketed for perineal use. These archives may be subject to corporate destruction policies, though litigation holds in active cases should preserve relevant materials.
What a Talc-Ovarian Cancer Case Is Worth
The Los Angeles trial produced a defense verdict with zero recovery for the plaintiffs. That is the honest starting point. But had the plaintiffs prevailed, the potential exposure would have been substantial, and understanding that potential helps you evaluate whether a claim is worth pursuing.
This trial: $0. The jury rejected liability, so no damages were awarded. No medical expenses, no lost earnings, no pain and suffering, no loss of consortium, no punitive damages. The families of the three decedents received nothing from this verdict.
What a plaintiff verdict in California could look like. Had the plaintiffs prevailed, three wrongful death claims in a California product liability case against a deep-pocket manufacturer would have included:
- Economic damages: Past and future medical expenses (surgery, chemotherapy, hospitalization, palliative care), lost earnings and lost earning capacity, funeral and burial costs. For ovarian cancer — a disease often diagnosed at an advanced stage with expensive treatment protocols and poor survival rates — these costs can be substantial.
- Non-economic damages: Pain and suffering, loss of society and companionship, loss of consortium. In California, these are uncapped in product liability cases. A jury can award whatever it believes fairly compensates the family for the human loss.
- Survival damages: The decedent’s pre-death pain and suffering — the period between diagnosis and death, which in advanced ovarian cancer can be months or years of treatment, physical decline, and awareness of mortality.
- Punitive damages: If the evidence showed J&J knew about cancer risks and consciously disregarded consumer safety, punitive damages would be on the table — and in California, they are uncapped in product liability cases.
A plaintiff verdict in a case like this — three wrongful deaths, no non-economic cap, a deep-pocket manufacturer, potential punitive exposure — could theoretically reach eight or even nine figures combined. The Ingham verdict ($4.69 billion for 22 plaintiffs, reduced to ~$2.12 billion) gives you a sense of the scale, though that case involved more plaintiffs and a different state’s law.
The broader settlement landscape. With more than 67,000 claims pending and J&J’s bankruptcy strategy abandoned, the question of global settlement values is live. This defense verdict may depress per-claim settlement offers across the docket, as J&J can point to it as evidence that juries are not uniformly persuaded by the plaintiffs’ science. But the Ingham verdict and other plaintiff verdicts push in the opposite direction. If you have a strong individual fact pattern, you should not assume the global settlement average reflects what your case is worth — a case with documented decades of perineal use, a clear pathology, and minimal alternative risk factors may be worth far more than the average.
Past results depend on the facts of each case and do not guarantee future outcomes. The Ingham verdict and any other verdict cited here are public records with their full procedural status stated. They are context for what these cases can be worth, never a promise of what yours will be.
The Defense Playbook: What J&J Does and How to Answer It
Johnson & Johnson has tried enough talc cases to have a well-developed defense playbook. Here are the plays you should expect and the counters that answer them.
Play 1: Attack general causation. J&J’s primary defense is that the scientific evidence does not establish that talc causes ovarian cancer. They bring elite epidemiologists who testify that the association is weak, inconsistent, and not statistically significant in the strongest studies. Counter: The plaintiffs’ experts must be top-tier epidemiologists and gynecologic oncologists who can explain why the consistency of modest elevated risk across dozens of case-control studies, combined with the biological plausibility of the talc-inflammation-cancer pathway and the IARC classification, supports a causal conclusion. The expert battle is the case — invest in the best experts and make sure their methodology survives the admissibility challenge.
Play 2: Point to alternative causes. Ovarian cancer has many risk factors — BRCA mutations, family history, age, reproductive history, hormone therapy, endometriosis. The defense will argue that the plaintiff’s cancer was caused by one of these factors, not by talc. Counter: Obtain the plaintiff’s complete medical and genetic history. If BRCA testing was done and is negative, that eliminates the strongest alternative cause. If there is no family history of ovarian or breast cancer, that weakens the genetic explanation. Build the specific causation case by排除 — eliminating alternative causes one by one until talc exposure is the most reasonable explanation remaining.
Play 3: Attack exposure evidence. The defense will argue that the plaintiff cannot prove sufficient duration, frequency, or method of talc use to support a causal connection. Decades after the fact, who can prove exactly how often they used baby powder and where they applied it? Counter: Gather every piece of exposure evidence available — family testimony about purchasing habits, photographs showing the product in the home, receipts (if any survive), the physical product containers themselves. Family members who can testify to decades of observed use are powerful witnesses. The exposure case does not have to be perfect — it has to be credible and consistent.
Play 4: Emphasize regulatory compliance. J&J will point out that the FDA has not banned talc in cosmetics, has not required ovarian cancer warnings, and that the product was sold legally for decades. Counter: The FDA’s cosmetic regulatory framework does not require pre-market safety testing or approval. The absence of FDA action is a regulatory gap, not a safety endorsement. J&J itself withdrew the product from the U.S. market in 2020 — and a jury can decide what to make of a company that pulls a product while insisting it is safe.
Play 5: Argue the statute of limitations has expired. If the plaintiff was diagnosed years ago, the defense will argue the clock has already run. Counter: The discovery rule — which may apply in California to claims involving latent diseases — can start the clock when the plaintiff discovered or should have discovered the connection between the disease and talc exposure, not when the disease was diagnosed. This is a fact-specific legal argument that requires careful analysis of the individual timeline.
The Proof Story: How a Talc Case Is Built
Here is how a talc-ovarian cancer case is actually built, from the first phone call through trial.
Week one: intake and timeline. The first conversation establishes the critical facts: when did the plaintiff (or decedent) start using talc-based baby powder? How often? Where on the body? For how many years? When was the ovarian cancer diagnosed? What is the pathology? What are the known risk factors — BRCA status, family history, reproductive history? When did the plaintiff first learn of the possible connection between talc and ovarian cancer? These facts determine whether a case exists and how strong it is.
The preservation letter. The first formal step is a preservation demand — a letter sent to J&J (and any other defendants) ordering them to preserve all relevant documents, internal communications, testing records, marketing materials, and product samples. This letter creates a legal duty to retain evidence. If documents are destroyed after the letter is received, the company faces spoliation sanctions — including adverse inference instructions that tell the jury they may assume the destroyed evidence would have been unfavorable to the company.
Medical records and pathology. The complete medical record is assembled — diagnosis records, surgical reports, pathology reports, chemotherapy records, imaging, and if available, preserved tissue blocks. A gynecologic pathology expert reviews the tissue to identify the cancer subtype and, in some cases, to look for talc particles in the ovarian tissue. The pathology is the medical spine of the case.
Expert recruitment. This is where talc cases are won or lost. The plaintiffs need at least three categories of expert: an epidemiologist who can testify that talc use is associated with increased ovarian cancer risk; a gynecologic oncologist or pathologist who can testify that talc caused this specific plaintiff’s cancer; and a toxicologist or industrial hygienist who can explain the exposure pathway and dose. Each expert must survive the defense’s admissibility challenge — and in California, that challenge can be fierce.
Discovery. Written discovery (interrogatories, requests for production) and depositions follow. J&J’s corporate representatives are deposed about internal testing, knowledge of cancer risk concerns, marketing decisions, and the 2020 withdrawal. The plaintiffs’ experts are deposed by the defense, and vice versa. The deposition transcripts become the ammunition for trial.
Bellwether or individual trial track. If the case is part of the MDL, it may be selected as a bellwether — a test case designed to help both sides assess settlement value. If it is an individual case in state court (as the Los Angeles case was), it proceeds on its own track. The Los Angeles trial shows what an individual trial looks like — three consolidated wrongful death claims, a jury in Los Angeles County, a defense verdict.
The number. If the case settles, the number is built from the strength of the exposure evidence, the quality of the medical records and pathology, the persuasiveness of the experts, the venue, and the defendant’s assessment of trial risk. If the case goes to trial, the number is whatever the jury decides — and as the Ingham verdict and this Los Angeles verdict show, that number can be enormous or it can be zero.
If You Used Talc Products and Developed Ovarian Cancer: Your First Steps
If you or a loved one used talc-based baby powder and was later diagnosed with ovarian cancer, the steps you take in the first weeks matter. This is not a crash scene — the evidence is different — but the urgency is real because the statute of limitations is running and physical evidence is degrading.
First: preserve the product. If you still have bottles or containers of talc-based baby powder — yours or a deceased family member’s — do not throw them away. Store them safely. These containers are physical evidence that can link a specific product to a specific user. Photograph the containers, the labels, and any lot numbers or manufacturing codes visible on the packaging.
Second: gather medical records. Request the complete medical record — not just the discharge summary, but the full chart, including pathology reports, surgical reports, imaging, chemotherapy records, and genetic testing results (BRCA status is critical). If tissue blocks are preserved, request that they be retained. Medical facilities destroy records on retention schedules — the longer you wait, the more evidence disappears.
Third: document the exposure history. Write down everything you can remember about talc use — when it started, how often it was used, where on the body it was applied, what brand, what size containers, where they were purchased, who else in the household used it. Talk to family members who can corroborate the use history. Decades of habitual use is the exposure case, and family testimony is often the most credible evidence because it comes from people who watched the routine daily.
Fourth: evaluate the deadline. If your loved one has passed away, the two-year wrongful death statute of limitations may be running from the date of death. If you are living with ovarian cancer, the limitations period may run from when you discovered or should have discovered the connection to talc. Either way, do not assume you have plenty of time. Talk to a lawyer who can evaluate your specific timeline.
Fifth: do not give a recorded statement to anyone. If J&J, its insurers, or any representative of the company contacts you, do not answer questions about your product use, your medical history, or your legal intentions. Anything you say can and will be used to undermine your case. Refer all communications to your lawyer.
Sixth: do not sign anything. No release, no settlement agreement, no authorization for medical records release to a third party. Some companies send settlement offers or release forms to potential claimants early — before they understand the value of their claim. Signing a release extinguishes your rights permanently.
If your situation involves toxic tort claims — which is exactly what a talc-ovarian cancer case is — the evaluation process is specific to this area of law and requires attorneys who understand both the science and the regulatory framework.
Frequently Asked Questions
Can I still file a talc lawsuit after this Los Angeles defense verdict?
Yes. This verdict does not prevent you from filing a claim. It is one jury’s decision in one trial. The broader talc litigation includes more than 67,000 pending claims, and the verdict record is mixed — some plaintiff verdicts, some defense verdicts. Your right to file is governed by the statute of limitations in your state, not by the outcome of this or any other individual trial. If you are within the applicable limitations period, you can file.
How long do I have to file a talc-ovarian cancer claim in California?
For wrongful death claims, California generally requires filing within two years of the date of death. For personal injury claims (if you are living with ovarian cancer), the limitations period may run from the date you discovered or should have discovered the connection between your disease and talc exposure — though this discovery rule is a legal argument that depends on your specific facts. Do not assume you have time. Talk to a lawyer who can evaluate your deadline.
Does this verdict mean the science is settled against talc causing cancer?
No. The science is genuinely contested. Some studies show a modestly elevated risk of ovarian cancer with perineal talc use; others show no statistically significant association. The International Agency for Research on Cancer has classified perineal use of talc-based body powder as possibly carcinogenic to humans. The Los Angeles jury was not persuaded that the causal link was established in this specific case — but other juries, looking at similar science, have reached the opposite conclusion. The science has not been settled by any court.
What makes a strong talc-ovarian cancer case?
A strong case has four elements. First, documented long-term perineal use of talc-based baby powder — ideally corroborated by family testimony or physical product containers. Second, a clear ovarian cancer diagnosis with pathology that supports the causal theory. Third, minimal or excluded alternative risk factors — negative BRCA testing, no significant family history of ovarian or breast cancer. Fourth, a timeline that fits — exposure preceding diagnosis by enough years for the alleged causal pathway to operate. No case has all four perfectly, but the stronger each element is, the better the case.
Can my family file if our loved one has already died from ovarian cancer?
Yes — if you are within the statute of limitations. California’s wrongful death statute allows certain surviving family members to file a claim: a surviving spouse, domestic partner, or children first; if none survive, then other heirs may be eligible. The two-year clock runs from the date of death. If your loved one died within the last two years, you may still be within the deadline. If more than two years have passed, you need a lawyer to evaluate whether any exception or tolling rule applies.
What if I used generic or store-brand talc powder, not Johnson & Johnson?
J&J’s baby powder is the most widely used talc-based product and the primary defendant in this litigation, but other manufacturers produced talc-based body powders as well. If you used a different brand, the legal analysis may differ — the defendant would be that manufacturer, not J&J — but the legal theories (failure to warn, design defect, negligence) are similar. Document what brand you used and discuss it with a lawyer.
How much is a talc-ovarian cancer case worth?
There is no single answer. The Los Angeles trial produced $0 because the jury rejected liability. Other trials have produced verdicts ranging from millions to billions. The value of an individual case depends on the strength of the causation evidence, the extent of the damages (medical expenses, lost earnings, pain and suffering, loss of consortium), the defendant’s assessment of trial risk, and whether punitive damages are on the table. In California, non-economic damages are uncapped in product liability cases, which means a strong case can have substantial value. Past results depend on the facts of each case and do not guarantee future outcomes.
Will I have to go to trial, or can these cases settle?
Some talc cases settle and some go to trial. J&J has attempted to resolve the entire talc docket through bankruptcy — three times, all failed — and has also engaged in settlement discussions at various points. Individual cases can settle before trial if both sides agree on value. But J&J has shown a willingness to try cases, and this Los Angeles verdict suggests the company is prepared to defend in court. Whether your case settles or goes to trial depends on its specific strength, the venue, and the defendant’s evaluation of risk.
Is it too late if I was diagnosed with ovarian cancer years ago?
Maybe not. The discovery rule — which may apply in California and other states to claims involving latent diseases — can start the limitations clock when you discovered or should have discovered the connection between your disease and talc exposure, not when you were diagnosed. If you only recently learned of the possible link between talc and ovarian cancer, you may still be within the deadline. This is a fact-specific legal question that requires evaluation by a lawyer in your state.
What evidence do I need to preserve?
Four categories. First, the physical product — any remaining bottles or containers of talc-based baby powder. Second, the complete medical record — pathology reports, surgical reports, imaging, chemotherapy records, genetic testing. Third, exposure documentation — your own written recollection of product use, family testimony, photographs showing the product in the home. Fourth, any correspondence or communications with J&J, its insurers, or any representative who may have contacted you about the product or your claim.
Why We Fight
This is a difficult case to win. The Los Angeles jury verdict tells you that. The science is contested, the defense is well-funded, and the company has shown it will fight every case. But difficulty is not the same as hopelessness — and the families who have won these cases won them because they had attorneys who understood the science, knew the corporate structure, invested in the right experts, and built the proof story from the ground up.
Ralph P. Manginello is the managing partner of our firm. He has been practicing law for 27-plus years, licensed since November 1998, and is admitted to federal court in the Southern District of Texas. He was a journalist before he was a lawyer — which means he knows how to find the document the company does not want found, and how to tell its story to a jury in language a real person understands. He has spent his career in courtrooms, including federal court, fighting for people hurt by corporate decisions. Read more about Ralph here.
Lupe Peña is an associate attorney at our firm, licensed since 2012. Before he joined our side of the table, he spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like the readers of this page. He knows how claims are valued from the inside, how the defense playbook works, and where the pressure points are. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. Read more about Lupe here.
We do not get paid unless we win your case. Our fee is a contingency — 33.33 percent before trial, 40 percent if the case goes to trial. The first consultation is free. We have live staff available 24 hours a day, 7 days a week — not an answering service, but people who can start helping you the moment you call. If we are not the right fit for your case, we will tell you — and we will help you find the firm that is.
We serve families in English and Spanish. Hablamos Español.
If you or someone you love used talc-based baby powder and developed ovarian cancer — whether in Los Angeles, anywhere in California, or anywhere in this country — the deadline may be running, the evidence may be fading, and the fight is real. Call us at 1-888-ATTY-911 (1-888-288-9911). The call is free. The conversation is confidential. And the clock on your rights does not wait.
This page is legal information, not legal advice. Every case is different. Past results depend on the facts of each case and do not guarantee future outcomes. Contacting the firm is free and confidential. We handle cases in California working with local counsel where required.